Biogen’s Royalty Payments On Tecfidera Still Hinge On Question Of Patent Timing
Executive Summary
$1.25bn settlement with Forward ensures Biogen will retain its MS product, but firm could end up paying more, depending on how courts come down on question of who filed first; as a practical matter Forward filed its US patent application for dimethyl fumarate first, but Biogen contends it began developing the active ingredient first, making it the effective first filer.
You may also be interested in...
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Xpovio Clinical Development Timeline
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.
Xpovio's US FDA Review: A Primer On How (Not) To Submit Real-World Data
Karyopharm included a real-world data study to support its Xpovio NDA, but the US FDA deemed the study inadequate for an overall survival comparison to the pivotal STORM trial.